These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
42. Uraemic tumoral calcinosis in a peritoneal dialysis patient. Zhou H; Yang M; Zou Y Intern Med J; 2018 Dec; 48(12):1544-1546. PubMed ID: 30517983 [No Abstract] [Full Text] [Related]
43. Oral calcium effectively reduces parathyroid hormone levels in hemodialysis patients: a randomized double-blind placebo-controlled study. Rudnicki M; Højsted J; Petersen LJ; Sørensen HA; Hyldstrup L; Transbøl I Nephron; 1993; 65(3):369-74. PubMed ID: 8289986 [TBL] [Abstract][Full Text] [Related]
44. Mineral and bone disorders in patients on dialysis: physiology and clinical consequences. McCarley PB; Arjomand M Nephrol Nurs J; 2008; 35(1):59-64. PubMed ID: 18372764 [TBL] [Abstract][Full Text] [Related]
45. Maxillary brown tumor of secondary hyperparathyroidism in a hemodialysis patient. Weiss RR; Schoeneman MJ; Primack W; Rozycki D; Bennett B; Greifer I JAMA; 1980 May; 243(19):1929-30. PubMed ID: 7365977 [No Abstract] [Full Text] [Related]
46. Possible role of inorganic sulphate in the pathogenesis of hyperparathyroidism in chronic renal failure. Michalk D; Tschöpe W; Böhles HJ; Mehls O Proc Eur Dial Transplant Assoc; 1981; 18():561-6. PubMed ID: 7329984 [TBL] [Abstract][Full Text] [Related]
47. When is Vitamin D Contraindicated in Dialysis Patients? Goodman WG Semin Dial; 2009; 22(3):245-7. PubMed ID: 19573000 [No Abstract] [Full Text] [Related]
48. When is Vitamin D contraindicated in dialysis patients? Khosla N; Sprague SM Semin Dial; 2009; 22(3):249-51. PubMed ID: 19573002 [No Abstract] [Full Text] [Related]
49. When is Vitamin D contraindicated in dialysis patients? Martin KJ Semin Dial; 2009; 22(3):247-9. PubMed ID: 19573001 [No Abstract] [Full Text] [Related]
50. The mechanisms of hyperphosphatemia-induced vascular calcification. Cozzolino M; Gallieni M; Brancaccio D Int J Artif Organs; 2008 Dec; 31(12):1002-3. PubMed ID: 19115191 [TBL] [Abstract][Full Text] [Related]
52. Treatment with sevelamer decreases bicarbonate levels in hemodialysis patients. Marco MP; Muray S; Betriu A; Craver L; Belart M; Fernández E Nephron; 2002 Oct; 92(2):499-500. PubMed ID: 12218343 [No Abstract] [Full Text] [Related]
53. [Long-term treatment of secondary hyperparathyroidism in the chronic hemodialysis patient with 1,25-(OH)2D3]. Giachino G; Giacchino F; Jeantet A; Del Piano A; Garetto A; Pellerey M; Piccoli G Minerva Med; 1985 Mar; 76(9-10):407-14. PubMed ID: 2984605 [No Abstract] [Full Text] [Related]
54. [Advances in blood purification medicine in 2008]. Shigematsu T; Negi S; Sakaguchi T; Oda H; Ohura M Nihon Jinzo Gakkai Shi; 2009; 51(1):27-32. PubMed ID: 19238905 [No Abstract] [Full Text] [Related]
55. How can the cardiac death rate be reduced in dialysis patients? Avram MM Semin Dial; 2002; 15(1):26-9. PubMed ID: 11874588 [No Abstract] [Full Text] [Related]
56. [Secondary hyperparathyroidism--risk factor for development of cardiovascular complications in patients on hemodialysis]. Petrović D; Stojimirović B Med Pregl; 2010; 63(9-10):674-80. PubMed ID: 21446098 [TBL] [Abstract][Full Text] [Related]